News Grifols files drug for rare bleeding disorder in the US Grifols has filed for FDA approval of its new drug for bleeding disorder acquired fibrinogen deficiency (AFD), aiming for a first-in-class US launch.
News Grifols eyes first place in US fibrinogen concentrate market Grifols is gearing up to file for approval of a drug for rare bleeding disorder acquired fibrinogen deficiency (AFD) that could provide a more reliable and easier treatmen
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.